Skip to content

Reslizumab

    Brands

    DEA Class; Rx

    Common Brand Names; Cinqair

    • Interleukin Inhibitors; 
    • Monoclonal Antibodies, Anti-asthmatics

    An intravenously administered humanized monoclonal antibody that targets interleukin 5 and reduces eosinophil-meditated inflammation of the airways
    Indicated in adults for add-on maintenance treatment of severe asthma with an eosinophilic phenotype
    Anaphylaxis has been reported as early as the second dose; monitor patients closely during and after infusion

    Indicated for asthma maintenance add-on therapy in severe asthma (eosinophilic phenotype).

    Known hypersensitivity to reslizumab or its excipients

    • Elevated CPK, transient (20%)
    • Treatment-emergent antibody response (5.4%)
    • Oropharyngeal pain (2.6%)
    • Musculoskeletal (2.2%)
    • Myalgias (1%)
    • Elevated CPK >10x ULN (0.8%)
    • Malignancy (0.6%)
    • Anaphylaxis (0.3%)

    Anaphylaxis reported observed during or within 20 minutes after completion of the IV infusion and reported as early as the second dose (see Black Box Warnings)

    Not for use to treat acute asthma symptoms or acute exacerbations

    No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of reslizumab; do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of reslizumab therapy

    Diverse malignancies observed with reslizumab vs placebo in clinical trials (0.6% vs 0.3%)

    Treat patients with pre-existing helminth infections before initiating reslizumab; if patients become infected during reslizumab treatment and do not respond to antihelminth treatment, discontinue reslizumab until infection resolves

    Data are insufficient regarding drug-associated risk during pregnancy

    Unknown if distributed in human breast milk; however, human IgG is known to be present in human milk

    Adults

    3 mg/kg IV infusion once every 4 weeks.

    Geriatric

    3 mg/kg IV infusion once every 4 weeks.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    Neonates

    Not indicated.

    Reslizumab

    IV solution

    • 100mg/10mL vial (10mg/mL)